| Ross Aron Schumer, MD | |
|
333 North West Street, Woodland Park, CO 80863 | |
| (719) 333-5042 | |
| Not Available |
| Full Name | Ross Aron Schumer |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 20 Years |
| Location | 333 North West Street, Woodland Park, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801920517 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Uch-memorial Health System | Colorado springs, CO | Hospital |
| Uchealth Grandview Hospital | Colorado springs, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Select Physical Therapy Holdings Inc | 9537076401 | 1487 |
| Poudre Valley Medical Group Llc | 9638208549 | 1605 |
News Archive
Agricultural subsidies are responsible for making those processed and energy-dense foods that contribute to the American epidemic of obesity the most affordable options for consumers, concludes a new study led by Dr. Mark J. Eisenberg, a cardiologist and epidemiologist at the Lady Davis Institute at the Jewish General Hospital in Montreal.
Sigma-Aldrich (Nasdaq: SIAL) today announced an agreement with Glycosan BioSystems for the sale of HyStem(TM), a fully customizable synthetic extracellular matrix (ECM) for stem cell research. HyStem offers researchers flexibility to tailor microenvironments for their cultured cells that mimic natural in vivo conditions, optimizing stem cell proliferation and differentiation. HyStem was developed by Glycosan BioSystems and will be sold by Sigma-Aldrich under a non-exclusive distribution agreement.
Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label, five-year safety and patient satisfaction study on Artefill for nasolabial fold (NLF) correction. The study assessed adverse events with Artefill starting at 6-months post treatment. Initial results show the incidence of adverse events with Artefill compare favorably to the current label, and that the majority of patients (88%) reported a high satisfaction rating. Upon completion, this will be the largest and longest duration prospective U.S. clinical study of any dermal filler.
The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.
About one in ten youths treated with an antipsychotic are diagnosed with autism spectrum disorder or intellectual disability. Conversely, one in six youths diagnosed with autism spectrum disorder has been prescribed antipsychotics.
› Verified 8 days ago
| Entity Name | Poudre Valley Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366763260 PECOS PAC ID: 9638208549 Enrollment ID: O20100602000122 |
News Archive
Agricultural subsidies are responsible for making those processed and energy-dense foods that contribute to the American epidemic of obesity the most affordable options for consumers, concludes a new study led by Dr. Mark J. Eisenberg, a cardiologist and epidemiologist at the Lady Davis Institute at the Jewish General Hospital in Montreal.
Sigma-Aldrich (Nasdaq: SIAL) today announced an agreement with Glycosan BioSystems for the sale of HyStem(TM), a fully customizable synthetic extracellular matrix (ECM) for stem cell research. HyStem offers researchers flexibility to tailor microenvironments for their cultured cells that mimic natural in vivo conditions, optimizing stem cell proliferation and differentiation. HyStem was developed by Glycosan BioSystems and will be sold by Sigma-Aldrich under a non-exclusive distribution agreement.
Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label, five-year safety and patient satisfaction study on Artefill for nasolabial fold (NLF) correction. The study assessed adverse events with Artefill starting at 6-months post treatment. Initial results show the incidence of adverse events with Artefill compare favorably to the current label, and that the majority of patients (88%) reported a high satisfaction rating. Upon completion, this will be the largest and longest duration prospective U.S. clinical study of any dermal filler.
The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.
About one in ten youths treated with an antipsychotic are diagnosed with autism spectrum disorder or intellectual disability. Conversely, one in six youths diagnosed with autism spectrum disorder has been prescribed antipsychotics.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ross Aron Schumer, MD 4102 Pinion Dr, Usaf Academy, CO 80840-2502 Ph: (719) 333-5042 | Ross Aron Schumer, MD 333 North West Street, Woodland Park, CO 80863 Ph: (719) 333-5042 |
News Archive
Agricultural subsidies are responsible for making those processed and energy-dense foods that contribute to the American epidemic of obesity the most affordable options for consumers, concludes a new study led by Dr. Mark J. Eisenberg, a cardiologist and epidemiologist at the Lady Davis Institute at the Jewish General Hospital in Montreal.
Sigma-Aldrich (Nasdaq: SIAL) today announced an agreement with Glycosan BioSystems for the sale of HyStem(TM), a fully customizable synthetic extracellular matrix (ECM) for stem cell research. HyStem offers researchers flexibility to tailor microenvironments for their cultured cells that mimic natural in vivo conditions, optimizing stem cell proliferation and differentiation. HyStem was developed by Glycosan BioSystems and will be sold by Sigma-Aldrich under a non-exclusive distribution agreement.
Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label, five-year safety and patient satisfaction study on Artefill for nasolabial fold (NLF) correction. The study assessed adverse events with Artefill starting at 6-months post treatment. Initial results show the incidence of adverse events with Artefill compare favorably to the current label, and that the majority of patients (88%) reported a high satisfaction rating. Upon completion, this will be the largest and longest duration prospective U.S. clinical study of any dermal filler.
The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.
About one in ten youths treated with an antipsychotic are diagnosed with autism spectrum disorder or intellectual disability. Conversely, one in six youths diagnosed with autism spectrum disorder has been prescribed antipsychotics.
› Verified 8 days ago
Dr. Benjamin C Meyer, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 16222 W Us Highway 24 Ste 220, Woodland Park, CO 80863 Phone: 719-365-1950 Fax: 719-365-1951 | |
Dr. Michael G Messner, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 333 North West St, Woodland Park, CO 80863 Phone: 719-686-2820 Fax: 719-686-2830 |